Findings

What do systematic reviews say?

4,315 questions · 23,557 findings · 2,311 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4,183 · 17.8%GRADE not reported 3,930 · 16.7%Very low 5,371 · 22.8%Low 5,787 · 24.6%Moderate 3,320 · 14.1%High 966 · 4.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Manual therapy, prescribed exercises or both vs placebo

Proportion with adverse events · lateral elbow pain

The review found no eligible studies for this question.

1 finding from 1 review

Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Manual therapy, prescribed exercises or both vs placebo

Proportion with a serious adverse event · lateral elbow pain

The review found no eligible studies for this question.

1 finding from 1 review

Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Manual therapy, prescribed exercises or both vs no intervention or minimal intervention

PainScale: VAS (0 to 10, 0 is no pain) · lateral elbow pain

1 finding from 1 review

Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 1023 participants
Low

Manual therapy, prescribed exercises or both vs no intervention or minimal intervention

DisabilityScale: 0 to 100 (0 is no disability) · lateral elbow pain

1 finding from 1 review

Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 732 participants
Low

Direct antivirals (grazoprevir and elbasvir) vs placebo

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Relapse · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

End‐of‐treatment response · patients on HD with HCV infection

Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 174.99 [11.03, 2775.78]
1 study · 173 participants
Low

Direct antivirals (grazoprevir and elbasvir) vs placebo

Sustained virological response · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Treatment discontinuation · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Preloading nicotine replacement therapy (NRT) vs standard‐use NRT

Smoking cessation · people who smoke

Preloading nicotine replacement therapy (NRT) probably leads to higher smoking cessation compared with standard‐use NRT (moderate certainty).

1 finding from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.25 [1.08, 1.44]
9 studies · 4395 participants
Moderate

Preloading nicotine replacement therapy (NRT) vs standard‐use NRT

Overall serious adverse events · people who smoke

Preloading nicotine replacement therapy (NRT) showed no clear difference in overall serious adverse events compared with standard‐use NRT (low certainty).

1 finding from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.11 [0.59, 2.09]
4 studies · 3908 participants
Low

Preloading nicotine replacement therapy (NRT) vs standard‐use NRT

Treatment withdrawal · people who smoke

It is very uncertain whether preloading nicotine replacement therapy (NRT) changes treatment withdrawals compared with standard‐use NRT (very low certainty).

1 finding from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.95]
1 study · 80 participants
Very low

Pregabalin 300 mg vs placebo

Pain score · women having medical abortion before 14 weeks' gestation

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Nausea · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.85 [0.33, 2.19]
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Vomiting · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (vomiting) compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.76 [0.35, 1.63]
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Diarrhoea · women having medical abortion before 14 weeks' gestation

Summary of findings table ‐ Pregabalin 300 mg showed no clear difference in gastrointestinal side effects (diarrhoea) compared with placebo (low certainty).

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
OR 0.82 [0.38, 1.76]
1 study · 107 participants
Low

Pregabalin 300 mg vs placebo

Complete abortion rate ‐ not reported · women having medical abortion before 14 weeks' gestation

The review found no eligible studies for this question.

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin 300 mg vs placebo

Induction to expulsion interval ‐ not reported · women having medical abortion before 14 weeks' gestation

The review found no eligible studies for this question.

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin 300 mg vs placebo

Unscheduled contact with care ‐ not reported · women having medical abortion before 14 weeks' gestation

The review found no eligible studies for this question.

1 finding from 1 review

Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found